p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
Joint Authors
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-06-17
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma.
Patients harbouring this genetic anomaly are commonly resistant to standard therapy.
Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities.
Small molecular compounds, especially, have gained popularity in its efficacy against myeloma cells.
For instance, promising preclinical results have steered both nutlin-3 and PRIMA-1 into phase I/II clinical trials.
This review summarizes different modes of p53 inactivation in myeloma and highlights the current p53-based therapies that are being utilized in the clinic.
Finally, we discuss the potential and promise that the novel small molecules possess for clinical application in improving the treatment outcome of myeloma.
American Psychological Association (APA)
Teoh, P. J.& Chng, Wee Joo. 2014. p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma. BioMed Research International،Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-493012
Modern Language Association (MLA)
Teoh, P. J.& Chng, Wee Joo. p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma. BioMed Research International No. 2014 (2014), pp.1-9.
https://search.emarefa.net/detail/BIM-493012
American Medical Association (AMA)
Teoh, P. J.& Chng, Wee Joo. p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-493012
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-493012